ARMP - Armata Pharmaceuticals Inc Stock Price, Fair Value and News

2.84USD-0.16 (-5.33%)Market Closed

Market Summary

USD2.84-0.16

Market Closed

-5.33%

ARMP Stock Price

View Fullscreen

ARMP RSI Chart

ARMP Valuation

Market Cap

102.7M

Price/Earnings (Trailing)

-1.29

Price/Sales (Trailing)

21.85

EV/EBITDA

31.18

Price/Free Cashflow

-2.19

ARMP Price/Sales (Trailing)

ARMP Profitability

EBT Margin

-1.47%

Return on Equity

140.82%

Return on Assets

-66.12%

Free Cashflow Yield

-45.6%

ARMP Fundamentals

ARMP Revenue

Revenue (TTM)

4.7M

Rev. Growth (Yr)

21.36%

Rev. Growth (Qtr)

-36.78%

ARMP Earnings

Earnings (TTM)

-79.6M

Earnings Growth (Yr)

-72.68%

Earnings Growth (Qtr)

-26.07%

Breaking Down ARMP Revenue

Last 7 days

-5.3%

Last 30 days

8.4%

Last 90 days

2.9%

Trailing 12 Months

14.1%

How does ARMP drawdown profile look like?

ARMP Financial Health

Current Ratio

0.38

Debt/Equity

-1.04

Debt/Cashflow

-0.69

ARMP Investor Care

Shares Dilution (1Y)

0.03%

Diluted EPS (TTM)

-2.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.7M	0	0	0
2023	5.1M	4.2M	4.1M	4.5M
2022	4.6M	5.4M	5.4M	5.5M
2021	1.7M	2.6M	3.6M	4.5M
2020	0	351.0K	587.0K	823.0K
2017	183.0K	108.0K	117.0K	115.0K
2016	479.0K	480.0K	366.0K	260.0K
2015	407.0K	408.0K	448.0K	475.0K
2014	163.0K	245.0K	327.0K	409.0K
2013	0	0	0	81.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

CEO	Dr. Deborah L. Birx M.D.
WEBSITE	armatapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Armata Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Armata Pharmaceuticals Inc? What does ARMP stand for in stocks?

ARMP is the stock ticker symbol of Armata Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Armata Pharmaceuticals Inc (ARMP)?

As of Fri Jul 26 2024, market cap of Armata Pharmaceuticals Inc is 102.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARMP stock?

You can check ARMP's fair value in chart for subscribers.

Is Armata Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARMP is over valued or under valued. Whether Armata Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Armata Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARMP.

What is Armata Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ARMP's PE ratio (Price to Earnings) is -1.29 and Price to Sales (PS) ratio is 21.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Armata Pharmaceuticals Inc's stock?

In the past 10 years, Armata Pharmaceuticals Inc has provided -0.262 (multiply by 100 for percentage) rate of return.